Record revenue and net income growth driven by higher patient volumes, strong performance in oncology, and SulAmérica integration. EBITDA and cash flow improved, with significant investments and dividends distributed. Share price surged 76.9% in 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.